Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach
The European Journal of Health Economics · 2023-07 · 24 (5) · 717-733
DOI: 10.1007/s10198-022-01504-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift The European Journal of Health Economics, online erschienen am 22.08.2022. Verfasst von Jui-Fen Rachel Lu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Business and Management and Department of Health Care Management, College of Management, Chang Gung University, Taoyuan City, T…. Hauptthemen laut MEDLINE: Reimbursement, Incentive, Diabetes Mellitus. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: ministry of science and technology, taiwan, freeman spogli institute for international studies, stanford university.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Pay-for-Performance (P4P) to better manage chronic conditions has yielded mixed results. A better understanding of the cost and benefit of P4P is needed to improve program assessment. To this end, we assessed the effect of a P4P program using a quasi-experimental intervention and control design. Two different intervention groups were used, one consisting of newly enrolled P4P patients, and another using P4P patients who have been enrolled since the beginning of the study. Patient-level data on clinical indicators, utilization and expenditures, linked with national death registry, were collected for diabetic patients at a large regional hospital in Taiwan between 2007 and 2013. Net value, defined as the value of life years gained minus the cost of care, is calculated and compared for the intervention group of P4P patients with propensity score-matched non-P4P samples. We found that Taiwan's implementation of the P4P program for diabetic care yielded positive net values, ranging from $40,084 USD to $348,717 USD, with higher net values in the continuous enrollment model. Our results suggest that the health benefits from P4P enrollment may require a sufficient time frame to manifest, so a net value approach incorporating future predicted mortality risks may be especially important for studying chronic disease management. Future research on the mechanisms by which the Taiwan P4P program helped improve outcomes could help translate our findings to other clinical contexts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Graduate Institute of Business and Management and Department of Health Care Management, College of Management, Chang Gung University, Taoyuan City, Taiwan.
- Department of Radiation Oncology, Chang Gung Memorial Hospital in Linkou, Taoyuan City, Taiwan.
- Graduate Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei City, Taiwan.
- Shorenstein Asia-Pacific Research Center, Freeman Spogli Institute for International Studies, Stanford University, and NBER, Stanford, CA, USA.
- Division of Metabolism, Chang Gung Memorial Hospital, Keelung, Taiwan.
- Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA. bchen@mailbox.sc.edu.
Förderung
- ministry of science and technology, taiwan
- freeman spogli institute for international studies, stanford university
Zitieren
APA
Lu, J. R., Chen, Y. I., Eggleston, K., Chen, C. H., & Chen, B. (2023). Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach. The European Journal of Health Economics, 24(5), 717-733. https://doi.org/10.1007/s10198-022-01504-3
Vancouver
Lu JR, Chen YI, Eggleston K, Chen CH, Chen B. Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach. The European Journal of Health Economics. 2023;24(5):717-733. doi:10.1007/s10198-022-01504-3
BibTeX
@article{Lu2023,
author = {Lu, Jui-Fen Rachel and Chen, Ying Isabel and Eggleston, Karen and Chen, Chih-Hung and Chen, Brian},
title = {Assessing Taiwan’s pay-for-performance program for diabetes care: a cost–benefit net value approach},
journal = {The European Journal of Health Economics},
year = {2023},
volume = {24},
number = {5},
pages = {717--733},
doi = {10.1007/s10198-022-01504-3}
}
EUVIMED